CCP
TAK icon

Corient Capital Partners’s Takeda Pharmaceutical TAK Stock Holding History

Corient Capital Partners’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$303K Hold
21,574
– – 0.02% 459
2022
Q2 		$303K Sell
21,574
-627
-3% -$8.95K 0.02% 472
2022
Q1 		$318K Buy
22,201
+2,599
+13% +$38.2K 0.02% 517
2021
Q4 		$267K Buy
19,602
+1,903
+11% +$26.7K 0.02% 563
2021
Q3 		$290K Buy
+17,699
New +$297K 0.02% 505

Other funds holding TAK

MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Corient Capital Partners's TAK Position: Q3 2022 in Review

Corient Capital Partners held its Takeda Pharmaceutical (TAK) position steady in Q3 2022 at 21,574 shares worth $303K. The position accounts for 0.02% of the portfolio, ranked #459.

Corient Capital Partners first reported a position in TAK in Q3 2021 and has held it in 5 quarters since. The position peaked at $318K in Q1 2022. 276 funds tracked by Wall St. Rank hold TAK as of Q3 2022.

  • Corient Capital Partners held 21,574 shares of Takeda Pharmaceutical worth $303K as of Q3 2022.
  • Corient Capital Partners left its Takeda Pharmaceutical share count unchanged in Q3 2022.
  • Takeda Pharmaceutical made up 0.02% of Corient Capital Partners's portfolio in Q3 2022, its #459 holding.
  • Corient Capital Partners first reported a position in Takeda Pharmaceutical in Q3 2021 and has held it in 5 quarters since.
  • Corient Capital Partners's Takeda Pharmaceutical position peaked at $318K in Q1 2022.
  • 276 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2022.

Based on Corient Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.